I had a few on the specifics but no time to get to that now. But my question involves that this was just a short-term study.
If the relative efficacy of M118 (and by use of the term efficacy I mean that it works and works with fewer adverse events and can be reversed quicker and with less hassles) remains as established in M118 it appears to me that we can expect to see a much larger advantage of M118 if utilized in patients who are followed for longer periods of time.
Is this an accurate expectation going forward into further clinical trials? Not necessarily as presently designed, but it appears that it would be a very telling trial to demonstrate the relative results in a study following patients over a longer duration.